Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PCSA (1-star) is a SELL. SELL since 3 days. Profits (-25.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.09% | Avg. Invested days 20 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.14M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 1.37 | 52 Weeks Range 0.15 - 3.10 | Updated Date 06/30/2025 |
52 Weeks Range 0.15 - 3.10 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.42% | Return on Equity (TTM) -192.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2299777 | Price to Sales(TTM) - |
Enterprise Value 2299777 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 26194400 | Shares Floating 9493342 |
Shares Outstanding 26194400 | Shares Floating 9493342 | ||
Percent Insiders 11.6 | Percent Institutions 9.05 |
Analyst Ratings
Rating 1 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals, Inc. was founded to develop products to improve the survival and/or quality of life for cancer patients. They use a regulatory science approach to efficiently develop oncology assets.
Core Business Areas
- Oncology Drug Development: Processa focuses on developing next generation chemotherapeutics to improve the efficacy and safety for cancer patients.
Leadership and Structure
David Young (CEO), Michael Floyd (Chief Medical Officer). The company has a management team focused on regulatory science and drug development.
Top Products and Market Share
Key Offerings
- Next Generation Chemotherapeutics: Processa's pipeline includes drugs targeting cancer. Market share data is not publicly available as the products are still in development. Competitors include established oncology companies with approved therapies like Pfizer (PFE), Novartis (NVS), Roche (ROG.SW).
Market Dynamics
Industry Overview
The oncology drug market is a large and growing market driven by an aging population and increased cancer incidence. High unmet medical needs and advancements in cancer treatment are key drivers.
Positioning
Processa Pharmaceuticals Inc is a small cap, clinical-stage biopharmaceutical company focused on oncology. Its competitive advantage is its regulatory science approach to efficiently develop oncology drugs.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Processa Pharmaceuticals is positioned to capture a small portion of this market if their drugs are approved.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on regulatory science
- Pipeline of oncology assets
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- FDA approval of drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
Competitors and Market Share
Key Competitors
- PFE
- NVS
- ROG.SW
- MRK
- BMY
Competitive Landscape
Processa faces competition from established pharmaceutical companies with larger resources. Processa's regulatory science approach could offer a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as Processa is focused on drug development and clinical trials.
Future Projections: Future growth is dependent on clinical trial outcomes and potential FDA approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for its drug candidates.
Summary
Processa Pharmaceuticals is a development-stage oncology company with promising pipeline of drugs. Their regulatory science approach is a key advantage. However, they face significant risks related to clinical trial outcomes and funding. Future success depends heavily on successful clinical trials and potential partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data for Processa is not publicly available due to the company's early stage and is therefore represented as 0.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.